As global markets navigate a complex landscape marked by busy earnings reports and economic data, the technology sector remains a focal point, with indices such as the Nasdaq Composite experiencing ...

It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...

AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...

On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Pamela, 73, has lived with Alzheimer’s for two years. David is an Alzheimer’s advocate. More medications are emerging to ...

"GMA" explores why more women are taking testosterone and what doctors are saying about the trend, with many seeking it after ...